Dr. Rizvi Discusses Pembrolizumab for Non-Small Cell Lung Cancer

August 29, 2014
Naiyer A, Rizvi,MD

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).

Rizvi says pembrolizumab is being explored in NSCLC in first-line and previously treated patients. The patients who express PD-L1 do very well on the agent, Rizvi says.

Pembrolizumab is also well tolerated in both first-line and pretreated NSCLC patients. The toxicity profile is favorable, Rizvi says, with low significant AE rates.


x